Join Servier and MassBio on November 4 for the “2025 Servier R&D Day” in the MassBioHub. At this event in Cambridge, Servier R&D leaders and business development leaders will deliver an overview of Servier’s pipeline, speak to what they look for in partners, and discuss collaborative successes with current partners.
What to expect:
Attendees will hear from Servier US CEO David K. Lee and EVP of R&D Claude Bertrand, followed by deeper dives into oncology, neurology, and Servier’s approach to research. A dynamic panel discussion will feature speakers from companies currently partnering with Servier:
- Elizabeth Buck (Black Diamond Therapeutics)
- Jean-Michael Gries (Aitia)
- Yang Zheng (Base4)
You’ll then have a chance to network with the Servier team during an evening reception.
What they’re saying:
“Advancing innovation in our industry is a grueling, difficult process. To truly make a difference for patients, the challenges of drug development need to be embraced head-on. As a private company led by a non-profit foundation, Servier is uniquely positioned to make investments that prioritize patients. This independence allows us to focus on cutting-edge science that drives therapeutic progress. We have established ourselves as leaders in treating rare cancers and are now taking our patient-centered approach in oncology to another therapeutic area that has been limited, neurology. We look forward to meeting and working with other decisively science driven companies.” – Claude Bertrand, Executive Vice President R&D and Chief Scientific Officer, Servier